Fresenius Medical Care AG (FMS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Organic Revenue Growth: 5% with contributions from both Care Delivery and Care Enablement.
Operating Income Growth: 11% increase, consistent with the expected phasing of the full year outlook.
Net Leverage Ratio: Improved to 2.8x, below the self-imposed target range.
Care Enablement Margin: Improved to 8.3%, entering the target margin band of 8% to 12%.
Same Market Treatment Growth (U.S.): Stable, with a 0.5% plus expected growth for 2025.
Same Market Treatment Growth (International): Accelerated to 2.5%.
Lives Under Management: Increased from around 130,000 to around 148,000 by the end of March.
Special Items Impact: Negatively affected group operating income by EUR126 million.
Operating Cash Flow: Increased by 28% against last year's quarter due to improved operating working capital.
Bond Issuance: Placed 2 bond tranches with an aggregate volume of EUR1.1 billion.
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Fresenius Medical Care AG (NYSE:FMS) reported strong organic revenue growth of 5% in Q1 2025, driven by both Care Delivery and Care Enablement segments.
The FME25 transformation program delivered EUR68 million in additional sustainable savings, contributing to the company's financial health.
Operating income grew by 11%, positioning the company well for future quarters.
The net leverage ratio improved to 2.8x, below the self-imposed target range, indicating strong financial discipline.
Care Enablement segment achieved a margin of 8.3%, entering its target margin band of 8% to 12% for the first time.
Negative Points
The severe flu season led to increased missed treatments, impacting same market treatment growth in the U.S.
Divestitures negatively impacted revenue development by 260 basis points.
Special items, including costs related to portfolio optimization and the FME25 transformation program, negatively affected group operating income by EUR126 million.
Labor and inflation costs offset some of the earnings developments in the Care Delivery segment.
The company faced a headwind from one less dialysis day in the quarter, affecting absolute volume development and utilization.
Q & A Highlights
Q: What are you seeing in April trading in the U.S., and how does this impact your confidence in the full-year guidance? A: The flu season hit hard in February and March, but we are encouraged by the underlying referrals, which are a strong leading indicator. We expect the mortality effect to show with a 6- to 8-week lag. We are confident in our positive trajectory and maintaining our 0.5% growth guidance for the year. - Helen Giza, CEO
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
44 minutes ago
- Bloomberg
Swedish Support for Joining Euro Fades as Krona Strengthens
Swedes' enthusiasm to adopt the euro fell for the first time in four and a half years after a recent run of strength for the krona, a survey showed. The share of Swedes who want to replace the krona with the euro fell to 32% from 34.4% a year earlier, according to the poll from Statistics Sweden on Wednesday. The share of proponents had a margin of error of 1.5%. Just under a half are against.
Bloomberg
44 minutes ago
- Bloomberg
EU Aims for US Trade Talks to Extend Past Trump's July Deadline
The European Union believes trade negotiations with the US to extend beyond President Donald Trump's July 9 deadline, even as the speed of the talks has increased over the past week. The EU sees reaching an agreement on the principles of a deal by July 9 as a best-case scenario, which would allow further talks to work out the details, according to people familiar with the matter. The US is expected to respond to the latest round of negotiations in the coming days and provide clarity on the next steps.
Bloomberg
an hour ago
- Bloomberg
Hungary's Inflation Rate Rises Again in Central Bank Challenge
Hungarian inflation accelerated in May for the first time in three months, underscoring central bankers' challenge in returning consumer price growth toward their target. The annual inflation rate rose to 4.4% from 4.2% in April, the Budapest-based statistics office said on Wednesday. The median estimate of 20 economists in a Bloomberg survey was a slight increase to 4.3%. Prices increased 0.2% on the month.
